Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other financing activities (2022 - 2023)

Seres Therapeutics' Other financing activities history spans 2 years, with the latest figure at -$529000.0 for Q3 2023.

  • For Q3 2023, Other financing activities fell 116.13% year-over-year to -$529000.0; the TTM value through Sep 2023 reached $3.3 million, changed N/A, while the annual FY2019 figure was $425000.0, N/A changed from the prior year.
  • Other financing activities for Q3 2023 was -$529000.0 at Seres Therapeutics, down from $304000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $3.3 million in Q3 2022 and bottomed at -$529000.0 in Q3 2023.